FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP 1s, which are not FDA approved and can pose risks to patients. FULL STORY:https: tinyurl.com 3ztf9uj2 The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics